Cytokinetics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 3, 2023. Cytokinetics is a late-stage biopharmaceutical company developing muscle-directed therapies and has not generated revenue from commercial product sales.
Financial results and liquidity
- Revenue: Q3 revenue was $0.4 million, down from $2.5 million in Q3 2022. Nine-month revenue was $5.9 million versus $92.6 million. The prior-year period included $87.0 million of one-time revenue from extinguishing a royalty obligation; 2023 revenue included a $2.5 million aficamten milestone from Ji Xing.
- Losses and expenses: Q3 operating loss was $122.3 million and net loss was $129.4 million, compared with $108.4 million and $142.3 million, respectively, in Q3 2022. Nine-month operating loss was $368.8 million and net loss was $389.3 million, versus $197.2 million and $251.6 million a year earlier. Basic and diluted net loss per share was $1.35 for Q3 and $4.07 for the nine-month period.
- Operating costs: Research and development expense rose to $82.5 million in Q3 from $62.7 million and to $245.1 million for nine months from $165.8 million, primarily reflecting cardiac program and clinical development spending. General and administrative expense was $40.1 million in Q3, down from $48.2 million; nine-month expense was $129.5 million, up from $124.0 million. Product margins are not meaningful because the company has no commercial product sales.
- Cash flow: Nine-month operating cash use was $340.3 million, compared with $201.3 million in 2022. Investing activities provided $320.7 million, mainly from investment maturities and sales; financing activities provided $52.5 million, including the $50.0 million aficamten royalty-transaction payment. Cash, cash equivalents and restricted cash ended at $100.1 million.
- Liquidity: Cash, cash equivalents and investments totaled $554.7 million at September 30, down from $829.3 million at December 31, 2022. Working capital was $483.7 million. Management said existing cash and investments were expected to fund requirements for at least 12 months after the filing. Subsequent to quarter-end, the company sold 2.45 million shares through its ATM facility for $80.3 million net proceeds through November 3.
- Debt and other obligations: Borrowings, net, totaled $609.0 million: a $60.9 million term loan and $548.1 million of convertible notes. The balance sheet also included $370.0 million of liabilities related to royalty purchase agreements. Stockholders’ deficit was $438.8 million.
Material changes and business developments
- Nine-month revenue fell sharply from 2022 because the prior-year period included the $87.0 million royalty-related accounting gain; meanwhile, R&D spending and operating cash use increased substantially.
- The FDA issued a Complete Response Letter for omecamtiv mecarbil in February 2023, stating that additional clinical evidence is needed to support approval for HFrEF. Cytokinetics submitted a formal dispute-resolution request; the outcome was uncertain. The CRL also made the $50 million and $25 million omecamtiv-related Royalty Pharma loan tranches unavailable. Up to $175 million of other tranches remained subject to development conditions.
- The company discontinued the Phase 3 COURAGE-ALS trial and its open-label extension in March 2023 after results indicated futility. Astellas had reached its maximum $12 million cost contribution; no further revenue was expected under that arrangement.
- Aficamten remained the principal advanced program: SEQUOIA-HCM enrollment was complete at 282 patients, with topline results expected by year-end 2023. MAPLE-HCM began enrolling in August, and ACACIA-HCM opened enrollment in September. The company also reported progress in early-stage cardiac programs.
Outlook, risks and unusual items
Management expects continued operating losses and cash outflows and anticipates substantial R&D spending, possible commercial-readiness costs, and potentially additional financing. It planned to file one to two INDs in 2023. The filing identifies financing availability, clinical-trial results and timing, regulatory decisions, manufacturing, collaboration-partner performance, competition, reimbursement and pricing as material uncertainties. The company has an accumulated deficit of approximately $2.0 billion and cautions that it may never achieve profitability.
Notable accounting items include the non-cash revenue-participation liability interest expense and the prior-year $87.0 million royalty-related revenue recognition. The company reported no material change in market-risk disclosures, no legal proceedings, and effective disclosure controls as of September 30, 2023.
Investor verification priorities
- SEQUOIA-HCM topline results and implications for aficamten’s development, financing tranches and regulatory path.
- FDA response to the omecamtiv mecarbil dispute-resolution request, and whether additional trials or other actions will be pursued.
- Cash burn, remaining liquidity after the post-quarter ATM issuance, and progress toward the stated 12-month funding horizon.
- Terms, repayment burden and conditions attached to the term loan, convertible notes and royalty-participation obligations.
- Enrollment, safety and efficacy outcomes in aficamten’s other Phase 3 trials, plus the timing and costs of commercial readiness.